COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon
Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, Christina Ellervik, Anja Poulsen, Troels Dirch Poulsen, Claus Henrik Nielsen
Topics & Concepts
RuxolitinibMedicineCytokine stormImmunologyMyelofibrosisPolycythemia veraInterferonContext (archaeology)CytokineDiseaseInternal medicineBone marrowInfectious disease (medical specialty)BiologyCoronavirus disease 2019 (COVID-19)PaleontologyMyeloproliferative Neoplasms: Diagnosis and TreatmentInflammasome and immune disordersCOVID-19 Clinical Research Studies